Ticker Symbol: SVRA
Savara Inc
$1.12 - 17-09-2024 4 p.m. ET
Exchange: NASDAQ
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0001160308
Company Profile
Savara is an orphan lung disease company. Its lead program, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Its management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 900 S Capital of Texas Hwy
Website: savarapharma.com
CEO: Robert Neville
Tags:
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Pricing
Last Updated: October 13, 2023 03:00 PM EST
Previous Close: $3.27
Change:
-
(
0.00%)
Days Range: $3.21 - $3.32
Beta: 0.78
52wk. High: $4.21
52wk. Low: $1.08
Ytd. Change 110.97%
50 Day Moving Average: $3.64
200 Day Moving Average: $3.04
Shares Outstanding: 135173441
Valuation
Market Cap: 44.2B
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A